| Company/Division name | FUJIFILM Diosynth Biotechnologies U.S.A. |
| Parent company | Fujifilm Corporation |
| Type of work | Manufacturing |
| If manufacturing, is the company a contract manufacturer? | Yes |
| Reshoring category: | Foreign Direct Investment |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring announced: | 2022 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 100 |
| Country(ies) from which reshored: | Japan |
| City reshored to: | Thousand Oak |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | allogeneic T-cell therapy |
